643 related articles for article (PubMed ID: 2960242)
1. New progestogens in oral contraceptives.
Runnebaum B; Rabe T
Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
[TBL] [Abstract][Full Text] [Related]
2. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
3. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
Prasad RN; Liew D; Ratnam SS
Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
[TBL] [Abstract][Full Text] [Related]
4. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
Chez RA
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1296-300. PubMed ID: 2524163
[TBL] [Abstract][Full Text] [Related]
5. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
6. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
7. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of the new progestogens in combination oral contraceptives.
Rebar RW; Zeserson K
Contraception; 1991 Jul; 44(1):1-10. PubMed ID: 1832625
[TBL] [Abstract][Full Text] [Related]
9. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
10. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
11. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
[TBL] [Abstract][Full Text] [Related]
12. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
London RS
Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
Corson SL
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the effects of a monophasic pill containing desogestrel plus 20 micrograms ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors.
Melis GB; Fruzzetti F; Nicoletti I; Ricci C; Lammers P; Atsma WJ; Fioretti P
Contraception; 1991 Jan; 43(1):23-31. PubMed ID: 1825970
[TBL] [Abstract][Full Text] [Related]
15. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
16. Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations.
Kloosterboer HJ; Rekers H
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):370-3. PubMed ID: 2142577
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576
[TBL] [Abstract][Full Text] [Related]
18. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
20. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
Janaud A; Rouffy J; Upmalis D; Dain MP
Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]